Researchers shed tears for cancer biomarkers

Mivision, an optical industry trade publication, tells us about a search for biomarkers within tears that could indicate diseases such as breast cancer. The research is being led by Mark Willcox, chief scientific officer at the Brien Holden Vision Institute in Sydney, Australia. The group, funded by the Australian Research Council, is studying whether proteins contained within tears change at the onset of diabetes, prostate cancer and breast cancer.

"We believe that the proteins expressed in tears may change during disease processes, and these changes could be useful in monitoring those at risk of getting disease, the progression of the disease, and the effectiveness of therapies to treat the disease," the researchers said in a statement appearing on Mivision.

The group writes that traditional prognostic markers--such as age at diagnosis, tumor size, hormonal receptor status and tumor grade--are not precise enough. "Molecular markers that can potentially be used to identify small lesions that are not visible with imaging techniques could provide an opportunity to treat breast cancer early, before it invades surrounding tissue, the researchers wrote.

Tears, specifically, are well-suited for the biomarker search, say the researchers, because they are easily and noninvasively collected and can be gathered multiple times to monitor cancer progression or regression. Also, tear proteins and peptides tend to be relatively small in size, more stable and less complex than those in serum.

- read more at Mivision

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.